Dr. Michael J. Thirman
Hematology & Oncology (Hematology & Oncology Physician)
5841 S Maryland Ave
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 93
Licensed in Illinois since 1990, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: University of Michigan Medical School
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036080940 (first issued 1990; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
Medical groups
- University of Chicago (1,712 clinicians)
- The University of Chicago Medical Center (915 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 93
- Services billed
- 436
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 259 | 40 |
| Established patient office or other outpatient visit, 30-39 minutes | 98 | 44 |
| Established patient office or other outpatient visit, 40-54 minutes | 89 | 32 |
| Telephone medical discussion with physician, 21-30 minutes | 68 | 12 |
| Established patient office or other outpatient visit, 20-29 minutes | 38 | 16 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 24 | 23 |
| Hospital discharge day management, 30 minutes or less | 18 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Venclexta (venetoclax) | 40 |
| Acyclovir Other prescribers in Chicago, IL | 39 |
| Imbruvica (ibrutinib) | 33 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Chicago, IL | 25 |
| Allopurinol Other prescribers in Chicago, IL | 19 |
| Calquence (acalabrutinib maleate) | 13 |
| Amlodipine Besylate Other prescribers in Chicago, IL | 12 |
| Fluconazole Other prescribers in Chicago, IL | 12 |
| Jaypirca (pirtobrutinib) | 12 |
| Potassium Chloride Other prescribers in Chicago, IL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 23 payments worth $19,023 in total to this clinician.
| Syndax Pharmaceuticals, Inc. | $13,772 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $2,870 |
| AbbVie Inc. | $1,731 |
| Daiichi Sankyo Inc. | $650 |
| Compensation for services other than consulting (speaking, faculty) | $9,404 |
|---|---|
| Consulting Fee | $7,951 |
| Travel and Lodging | $1,136 |
| Food and Beverage | $532 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Sep 5, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,600 |
| Syndax Pharmaceuticals, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,600 |
| AstraZeneca Pharmaceuticals LP Jun 10, 2025 | Consulting Fee CALQUENCE · Oncology | $2,870 |
| Syndax Pharmaceuticals, Inc. Dec 6, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,800 |
| AbbVie Inc. Jun 16, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,088 |
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Syndax Pharmaceuticals, Inc. Aug 16, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $565 |
| AbbVie Inc. Mar 25, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $544 |
| Syndax Pharmaceuticals, Inc. Oct 20, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN | $354 |
| Syndax Pharmaceuticals, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $124 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Dec 6, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,800 |
| Syndax Pharmaceuticals, Inc. Dec 6, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ORLANDO, FL | $23.43 |
| Syndax Pharmaceuticals, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,600 |
| Syndax Pharmaceuticals, Inc. Oct 20, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN | $354 |
| Syndax Pharmaceuticals, Inc. Oct 20, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN | $91.82 |
| Syndax Pharmaceuticals, Inc. Oct 20, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN | $76.06 |
| Syndax Pharmaceuticals, Inc. Oct 20, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN | $25.76 |
| Syndax Pharmaceuticals, Inc. Sep 5, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,600 |
| Syndax Pharmaceuticals, Inc. Aug 16, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $565 |
| AbbVie Inc. Jun 16, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,088 |
| AstraZeneca Pharmaceuticals LP Jun 10, 2025 | Consulting Fee CALQUENCE · Oncology | $2,870 |
| Daiichi Sankyo Inc. Apr 10, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| AbbVie Inc. Mar 25, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $544 |
| Syndax Pharmaceuticals, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $124 |
| Syndax Pharmaceuticals, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $43.03 |
| Syndax Pharmaceuticals, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $33.37 |
| Syndax Pharmaceuticals, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $3.95 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $428,000 in research payments for these studies, mostly to the institutions running them.
- A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the combination of Pembrolizumab with TGR-1202 in patients with relapsed/refractory CLL and B-Cell Non-Hodgkin Lymphoma (…
Merck Sharp & Dohme LLC - A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NP…
Janssen Research & Development, LLC - A First in Human Study of the MeninKMT2A MLL1 Inhibitor JNJ75276617 in Participants with Acute Leukemia
Janssen Research & Development, LLC - A phase 1/2, open-label, dose-escalation and dose-expansion cohort study of SNDX-5613 in patients with relapsed/refractory leukemias, including those harboring an mll/KMT2A gene rearrangement or nucleophosmin 1 (NPM1)…
Syndax Pharmaceuticals, Inc. - Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT06068868 - Expanded access program FORSNDX-5613IN patients with relapsed/refractory acute leukemias with genetic alterations associated with hoxa overexpression
Syndax Pharmaceuticals, Inc. - A phase 1, open-label, dose-escalation, and dose-expansion study to evaluate safety, tolerability, and clinical activity OFSNDX-5613IN combination with intensive chemotherapy in participants with newly diagnosed acute…
Syndax Pharmaceuticals, Inc. - A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie Inc. · Terminated · NCT03484520
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.